http://www.gosreports.com
Global Biosimilar Drug Market Worth USD$ 2860 Million By 2020
Biosimilar Drug (also known as follow-on biologic or subsequent entry biologic) is a biologic medical product which is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original “innovator” products, and can be manufactured when the original product’s patent expires. 
The increasing chronic diseases and rising population are the vital factors to drive the Biosimilar Drug market, according to a brand new research, the global Biosimilar Drug market is expected to worth USD$ 2860 million by 2020. 


The Full Report:
http://www.gosreports.com/global-medical-device-connectivity-market-research-report-2017/
……………………On the basis of type, the biosimilar monoclonal antibodies and insulin submarkets are projected to be the fastest growth segments, From 2014, many companies will try to launch monoclonal antibody biosimilars, with most targeting Roche’s Rituxan (rituximab) and Herceptin (trastuzumab), and Remicade for competition.  By 2020, biosimilar monoclonal antibodies (mAbs) and insulin products will account for 46% of the global biosimilars market.
Geographically, The EU is predominant of the market thanks to their pharmaceutical giants took colossal investments on Biosimilar R&D, and established mature market, Biosimilar erythropoietins and filgrastim products are already available in the EU, Japan and other developed markets and achieve limited revenues compared with their reference biologics. The launch of these biosimilars in the US will drive growth from 2014, as will the launch worldwide of second generation filgrastim (pegfilgrastim) and epoetin alpha (darbepoetin alpha) biosimilars.
The biosimilar human growth hormone submarket will be the slowest-growing of the leading market sectors. Sandoz’s growth hormone biosimilar, Omnitrope (somatropin) was the first biosimilar launched in many major markets, from 2004 onwards. That drug has achieved limited market penetration, though.
Global Biosimilar Drug market share by region as following:

Read Full Report: http://www.gosreports.com/global-biosimilar-drug-market-research-report-2016/
http://www.gosreports.com/global-biosimilar-drug-market-research-report-2017/
Joanna | Executive – International Business and partner Relations
E-mail: [email protected] | Tel: 510-400-8520
Web: www.gosreports.com
________________________________________________

More Information:
http://www.gosreports.com/global-mgoh2-market-research-report-2017/

Contacts Us
Joanna | Executive - International Business and partner Relations
E-mail: [email protected] 
Tel: 001-510-400-8520
Web: www.gosreports.com